212 related articles for article (PubMed ID: 31659068)
21. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of peripheral blood Kisspeptin mRNA and plasma CA125 protein for detection of epithelial ovarian cancer in patients who have ever been pregnant.
Chen L; Liu M; Ji J; Lin W; Shan F; Liu H
Neoplasma; 2016; 63(6):999-1006. PubMed ID: 27596301
[TBL] [Abstract][Full Text] [Related]
23. Serum CA125 in combination with ferritin improves diagnostic accuracy for epithelial ovarian cancer.
Zhao J; Guo N; Zhang L; Wang L
Br J Biomed Sci; 2018 Apr; 75(2):66-70. PubMed ID: 29452533
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
[TBL] [Abstract][Full Text] [Related]
25. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
26. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
27. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
28. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
Zhao D; Wang X; Zhang W
BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
30. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
Lv XL; Zhu Y; Liu JW; Ai H
Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
[TBL] [Abstract][Full Text] [Related]
31. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
32. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
Kataoka T; Watanabe Y; Hoshiai H
J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
34. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
35. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer.
Chen K; Gentry-Maharaj A; Burnell M; Steentoft C; Marcos-Silva L; Mandel U; Jacobs I; Dawnay A; Menon U; Blixt O
J Proteome Res; 2013 Mar; 12(3):1408-18. PubMed ID: 23360124
[TBL] [Abstract][Full Text] [Related]
36. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
Zou L; He X; Zhang JW
Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
39. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
[TBL] [Abstract][Full Text] [Related]
40. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
